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A STUDY OF THE CUTANEOUS EFFECTS OF BRADYKININ*
J. C. MITCHELL, M.D. AND H. KRELL
Five pharmacological actions have been at-
tributed to bradykinin (1). They are smooth
muscle stimulation, vasodilatation, increase in
capillary permeability, accumulation and migra-
tion of leukocytes and production of pain. In a
review of previous literature (2) on the cutaneous
effects of bradykinin, some differences were noted
between the reported results, and brief menticn
was made of unpublished observations that pain
but not itching was produced by intradermal
injection and by surface application of various
dilutions of synthetic bradykinin to the tape
stripped skin. Whereas biological preparations
had been used by previous workers (3), the
current availability of synthetic bradykininf pro-
vided an opportunity for further study and this
report amplifies the earlier observations.
Bradykinin is released by the action of an
enzyme, kallikrein, on a-2-globulin present in
plasma and in intercellular fluid. Some experi-
ments were carried out with biological prepara-
tions of kallikrein and kallikrein-inactivator.
METHODS AND MATERTALS
Twenty-one white adults, 9 healthy and 12 with
various dermatoses were studied. No consistent
differences were noted between the two groups.
Subjects were tested by intradermal injection of
0.1 ml of various concentrations of synthetic
bradykinin. Test sites were the volar surface of
the forearm and the upper back over the scapula.
Bradykinin solution (0.075 mgm per ml) was
diluted with isotonic sodium chloride USP (Na-
deau®). Concentrations were expressed in pg per
ml for injection and as a dilution fraction for sur-
face application. The diluent was used for control
injections and applications.
The method of Muller and Kierland (4) was
used to test for sweating. Jontophoresis was
carried out with a metal disc 5 X 4 cm, positive
pole, 2—6 milliamps galvanic current applied for
varying periods up to 5 minutes. The negative
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pole was a metal disc, 7 X 5 cm, with tap water as
wetting agent.
Cutaneous microcirculation was examined by
capillary microscopy using the technic described
by Davis and Lawler (5). Bradykinin was applied
by dropping it onto a site from which the keratin
had been removed by Scotch Tape®.
Padutin®t: Biologically prepared pancreatic
tissue extract, biologically standardized by the
vasodilator effect of kallikrein. Ten units were
dissolved in 5 ml isotonic saline for test purposes.
Trasylol9: Biologically prepared kallikrein-
inactivator (1,000 units per ml). The substance is
a polypeptide which inhibits kallikrein, trypsin
and some other enzymes. The solution was used
in the concentration supplied by the maker for
test purposes.
RESULTS
(a) Intradermal injection of bradykinin. All
the subjects tested responded to bradykinin. A
burning pain was experienced 15 to 30 seconds
after injection and persisted for up to three
minutes. Within one minute after injection, a
flare appeared in some subjects. A wheal appeared
about three minutes after injection, gradually
increased in size during the following 5 to 10
minutes and eventually reached a diameter two
to three times greater than that of the original
injection wheal. The wheal remained visible for
several hours and palpable for up to 9 hours. The
size of the initial injection wheal, which resulted
from injection of 0.1 ml of any solution, varied
from 0.6 cm to 0.8 cm diameter.
Pain
A burning pain, sometimes described as prick-
ing, occurred with intradermal injections of 0.1
ml isotonic saline containing 3.8 pg, 2.5 jig, 0.68
pg, 0.49 jig, and 0.16 jg bradykinin. Injection of
control isotonic saline produced an initial sting
at the time of injection but no subsequent pain.
Three physicians and one medical student took
part in the study and they, and all the other sub-
jects, even when directly questioned about
itching, did not describe the sensation as an itch
177
t Marketed by Winthrop Laboratories, 1450
Broadway, New York, 18, N.Y.§ Supplied by Farbenfabriken Bayer AG,
Levenkusen, Germany.
178 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
but rather as a burning pain. The pain was felt
more quickly, but not before the passage of 15
seconds, with the stronger concentrations. Injec-
tions of 0.1 ml isotonic saline containing 0.049 jig
bradykinin did not produce pain.
Wheat
This was a much more constant reaction than
the flare and the size and duration were propor-
tional to the quantity of bradykinin injected.
The wheal remained the same size for two to
three minutes, then it increased in size, becoming
more elevated and more readily palpable, and at
the same time greater in diameter. The wheal
continued to increase in size for up to ten minutes
reaching an eventual size two to three, and in a
few instances four, times that of the original.
The wheal persisted for up to nine hours and
usually remained palpable for several hours after
it was no longer visible. The usual duration of
visibility of the wheal was under two hours. In
one healthy physician subject, wheals persisted
after injections of 3.8 g bradykinin for up to 9
hours. Injection of a quantity of bradykinin which
was insufficient to cause pain, that is 0.049 Mg,
induced a wheal. In some instances wheals in-
duced by this dilution (1 in 1,000,000) did not
appear to increase in size but they were still
palpable one hour after injection.
Flare
This was much more variable than the wheal.
In some individuals it was absent. It usually
appeared 30 seconds after injection. In a group of
experiments using 0.68 g bradykinin the flare
measured 1.1, 2.4, 1.0, 1.5, 1.0, 1.0, 4.5 em in six
patients. The smaller flares became replaced by
the wheals as the latter enlarged. The larger
flares surrounded the wheals and lasted for up to
20 minutes. The presence or absence and size of
the flares did not appear to be proportional to the
amount of bradykinin injected but represented
an individual response.
One subject developed a flare 2 x 3 cm diameter
which lasted 40 minutes on the left upper outer
arm; in the same subject, injection of the same
quantity of bradykinin at the volar surface of the
left forearm induced a flare 1 cm diameter which
lasted 8 minutes.
Sweating
In four subjects intradermal injection of 3.8
Mg bradykinin did not affect local sweating.
Sweat imprints were made with the patient at
room temperature. Sweat droplets were absent
at the site of the wheal but were present in a
normal distribution pattern around the wheal.
Tests were made at adjacent sites in the same
individuals with methacholine chloride 1 in 200
and the expected hyperhidrosis was observed.
Relative Sizes of Reaction at Two Skin Sites
Herxheimer (6) made measurements of the
sizes of wheals which occurred following the
injection of 5 Mg bradykinin into the volar sur-
face of the forearm and the scapular skin, and
found that wheals were consistently larger at the
latter site.
Making the maximum effort to ensure detailed
accuracy of the technic, a similar comparison
was made of the sizes of wheals which resulted
from injection of 0.682 Mg bradykinin at the same
sites (Figure 1).
(b) Application of bradykinin to the tape-
stripped skin. The volar surface of the forearm
was shaved when necessary. Cellophane tape was
repeatedly applied to and then removed from the
same area of skin (0.5 x 2 inches) until a glisten-
ing erythematous surface was observed. Twenty
to forty-five strips were required. Thirty to forty-
five seconds after bradykinin solution had been
dropped onto the skin, a burning pain was ex-
perienced and this continued for up to three
minutes. The concentrations of bradykinin re-
quired to produce pain were comparable with
those used for injection. Dilutions of 1 in 13,333,
1 in 120,000, 1 in 200,000 and 1 in 600,000 regu-
larly produced pain but a dilution of 1 in
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1,000,000 did not. Use of dilution 1 in 13,333
produced whealing at the site of application and
the wheals persisted for up to 10 minutes. No
flares appeared on the normal skin around the
tape-stripped skin. Application of bradykinin to
skin which had been tape-stripped 24 hours pre-
viously produced pain of delayed onset; this
appeared about 45 seconds after application and
lasted a shorter time. Applications to skin which
had been tape-stripped 48 or more hours pre-
viously and to intact skin produced no pain.
(c) lontophoresis of bradykinin. To confirm
the efficacy of the equipment, histamine 1 in
20,000 was applied by iontophoresis and produced
the expected response.
Bradykinin, 1 in 260,000 in isotonic saline,
applied with 2 to 3 milliamps for 2J minutes,
produced erythema not significantly different
from that from isotonic saline alone; but transient
pink whealing occurred at the test and not at the
control site. Bradykinin was incorporated into
an ointment (0.075 mgm bradykinin, 4 ml iso-
tonic saline, 5 gms Hydrophilic ointment USP
XIV). Application with 5 miUiamps for 5 minutes
resulted in more erythema than at the site of
application of a control ointment and in addition
the appearance of red and white confluent wheal-
ing. Pseudopodia were not observed as with the
histamine response but no attempt was made to
quantitate the reaction by finding equivalent
dilutions of the two substances, because of the
several variables inherent in the technic.
(d) Capillary microscopy. Healthy subjects
only were used. The volar surface of the forearm
was tape-stripped as in (b) above. One hour was
allowed to elapse while the erythema directly
due to trauma subsided. The normal capillaries
of the skin were observed through isotonic saline
under a cover-slip. When bradykinin 1 in 200,000
was applied, the capillaries became indistinct and
ill-defined in a hazy pale background. It was not
possible to observe whether any alteration in
number or caliber of the capillaries took place
owing to the haziness of the field.
Tests with Padutin® solution. Nine subjects
were injected intradermally with 0.1 ml at the
volar surface of the forearm. Pain was not ex-
perienced. Flare was absent in six subjects and
in three there was a red rim around the wheal.
During three to five minutes after injection, the
wheals increased in size to an average diameter
of 1.05 cm (minimum 0.9 cm, maximum 1.2 cm).
The wheals remained the same size for a further
five minutes that is, for 10 minutes after inj cc-
tion, and gradually faded, being visible for 1 hour
and palpable for up to two hours. The wheals at
control sites at which isotonic saline solution was
injected did not increase in size and disappeared
in less than 20 minutes. No alteration of the
normal pattern of sweating occurred.
Tests with Trasylol® solution
Four subjects were injected intradermally with
0.1 ml at the volar surface of the forearm. Three
subjects experienced itching. Flares 2 cm, 3 em,
3 cm, and 4 cm, diameter and wheals 1.2, 1.1,
1.1, and 1.7 em diameter were observed. In
two of these subjects and in one other subject
who was not injected intradermally, Trasylol®
10,000 units was administered by slow intra-
venous drip during the course of some other ex-
periments. The subjects experienced no reaction.
DISCUSSION
The results reported here are not in agreement
with previous findings (3) that bradykinin is
pruritogenic; but are in accord with previous
reports of the pain-producing effect of plasma
kinins (7).
Fox and Hilton (8) observed that human sweat
contains a plasma kinin forming enzyme. Arthur
and Shelley (9) described the pruritogenie effects
of Mucuna pruriens and following the isolation of
the proteinase, mueunain, observed that the
endopeptidases as a class were pruritogenie when
introduced superficially into human skin. They
considered that proteinases were key agents in the
peripheral production of itching. Our findings
would not support their suggestion that pruritus
in sweat retention may be partly due to release
into the epidermis of the substance found in
sweat by Fox and Hilton, if this substance is
comprised of bradykinin only.
Release of bradykinin during ecerine gland
secretory activity is considered to be responsible
for some of the vasodilatation which occurs in
human skin during exposure to heat (8). Brady-
kinin is not itself a stimulus to sweating.
Attempts to observe the effects of exposure of
the superficial capillaries to bradykinin were
unsuccessful. The haziness of the background
which developed and which obscured the micro-
vaseulature was presumed to be due to edema,
since application of bradykinin in greater concen-
tration to the tape-stripped skin resulted in frank
whealing. It may be noted that induced vasodila-
180 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
tation is not necessarily accompanied by visible
changes in the superficial capillaries. Rapp et at.
(10) observed erythema following the application
of tetrahydrofurfuryl nicotinate, but microscopic
examination failed to reveal any changes in the
capillary vessels at any time regardless of the
duration of the erythema.
Maibach and Kligman (11) stated that repro-
ducibility of the cutaneous reactions of histamine
must depend on exact quantitation of the dose
administered. The exact size of an initial injec-
tion wheal may depend on factors other than the
dosage given, including the adhesiveness of the
prickle cells at the particular test site selected.
Our tuberculin-type syringes were tested for
leakage by the method described by Guld and
Rud (12), but the injection wheals varied in size.
The syringe recommended by Kligman, the
'Agla' Micrometer syringe (Burroughs Welcome
and Co.), is being used exclusively in further
studies. Herxheimer's findings may also be sub-
ject to the same objection. Comparison of his
findings that the wheal on the scapular skin was
considerable larger than the wheal on the forearm
skin with ours indicates that this difference is only
brought out with the larger doses which he em-
ployed.
Pain produced by application of bradykinin to
the tape-stripped skin is comparable to that
produced by application of this substance to the
floor of a eantharidinblister (7).
Trasylol® is in current clinical use for the relief
of shock attributed to the release of plasma kinins
in acute pancreatitis. Since the substance is a
protein substance of animal origin, skin tests for
sensitivity may be considered desirable before
therapy is started. Intradermal injection of
Trasylol® results in a reaction which might be
considered "a positive skin test" of the immediate
type, but it is possible that this may be the out-
come of its vascular activity on a basis other than
allergic.
Summary
The cutaneous effects of intradermal injection
and surface application of bradykinin were
studied. Burning pain, but no itching, was ex-
perienced. The wheal increased in size in the
period 3 to 10 minutes after injection. The size
of the wheal was proportionate to the dose in-
jected. The flare was inconstant in appearance
and size and appeared to he an individual re-
sponse. Whealing followed iontophoresis and
surface application to the tape-stripped skin.
Some observations were made on the cutaneous
effects of kallikrein and kallikrein-inactivator.
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